Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -3.09% and Operating profit at 8.04% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -1.13
Flat results in Sep 26
Risky - Negative EBITDA
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
INR 6 Cr (Micro Cap)
8.00
19
0.00%
-0.04
17.88%
1.39
Total Returns (Price + Dividend) 
Latest dividend: 1 per share ex-dividend date: Sep-12-2018
Risk Adjusted Returns v/s 
Returns Beta
News

Brawn Biotech Ltd Hits New 52-Week High of Rs 26.64 on Back of Strong Technical Signals
From a 52-week low of Rs 17.71 to a fresh high of Rs 26.64, Brawn Biotech Ltd has delivered a 33.2% gain over the past year, significantly outperforming the Sensex which declined 14% in the same period. This rally, culminating in a new 52-week peak on 28 Oct 2026, is underpinned by a broad alignment of technical indicators signalling sustained momentum.
Read More
Broad-Based Technical Strength Lifts Brawn Biotech Ltd to 52-Week High of Rs 25.7
Surging to a fresh 52-week high of Rs 25.7 on 6 Oct 2026, Brawn Biotech Ltd has demonstrated notable price momentum, outperforming its sector despite a modest underperformance on the day. This milestone caps a year-long rally that has delivered a 14.22% return, comfortably ahead of the Sensex’s 11.13% decline over the same period.
Read More
Broad-Based Technical Strength Lifts Brawn Biotech Ltd to 52-Week High of Rs 24.74
With a decisive surge to Rs 24.74 on 1 Oct 2026, Brawn Biotech Ltd has reached a fresh 52-week high, marking a notable milestone in its price momentum. This rally has been fuelled by a confluence of bullish technical indicators and sustained gains over the past three sessions, even as the broader market struggles to find footing.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
07-Nov-2026 | Source : BSENEWSPAPER PUBLICATION FOR UN-AUDITED FINANCIAL RESULTS FOR QUARTER AND HALF YEAR ENDED 30TH SEP 2026
Board Meeting Outcome for Outcome Of Board Meeting Held On 5Th November 2026 To Consider And Approve Inter-Alia Un-Audited Financial Results Of The Company For Quarter Ended September 30 2026.
05-Nov-2026 | Source : BSEOutcome Of Board Meeting Held On 5th November 2026 To Consider And Approve Inter-Alia Un-Audited Financial Results Of The Company For Quarter Ended September 30 2026.
Intimation Regarding Non-Applicability Of Regulation 23(9)
05-Nov-2026 | Source : BSEIntimation regarding non-applicability of regulation 23(9)
Corporate Actions 
No Upcoming Board Meetings
Brawn Biotech Ltd has declared 10% dividend, ex-date: 12 Sep 18
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 1 Schemes (0.35%)
Held by 0 FIIs
Brij Raj Gupta (16.69%)
Investor Education And Protection Fund (iepf) (14.4%)
30.53%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is -7.57% vs 207.07% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is -80.00% vs -74.14% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 45.24% vs -27.91% in Sep 2024
Growth in half year ended Sep 2025 is 135.63% vs -45.00% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 33.93% vs -14.18% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 127.69% vs -7.44% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 26.06% vs -18.31% in Mar 2025
YoY Growth in year ended Mar 2026 is 152.22% vs -16.88% in Mar 2025